GeneDx (WGS)
Runs exome and genome testing for pediatric and rare-disease diagnosis.
$92.00
After hours+1.26 (+1.39%)
At close$90.74(−7.25%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 106.49% | 31.76M shares | |
|---|---|---|---|
| 240 holders · as of Jun 30, 2026 | |||
| Insiders | 42.69% | 12.73M shares | |
| 10 holders · as of Sep 18, 2026 | |||
| Strategic holders | 7.28% | 2.17M shares | |
| 1 holder · as of Sep 18, 2024 | |||
| Adds to | 156.46% | ||
29.82M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 156.46%; nothing is left for Other.
13F, as of Jun 30, 2026
240 holders · 31.76M shares · 59 new positions · 144 increased · 61 reduced · 74 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Corvex Management LP | 4.78M | 16.04% | +1.56M | Aug 14, 2026 |
| Casdin Capital, LLC | 3.71M | 12.43% | +700.0K | Aug 14, 2026 |
| BlackRock, Inc. | 1.71M | 5.72% | +155.5K | Aug 7, 2026 |
| Goldman Sachs Group Inc | 1.67M | 5.60% | +334.5K | Aug 14, 2026 |
| Ark Investment Management LLC | 1.61M | 5.40% | +285.6K | Aug 14, 2026 |
| William Blair Investment Management, LLC | 1.40M | 4.70% | +625.4K | Aug 12, 2026 |
| Morgan Stanley | 988.3K | 3.31% | +456.1K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 879.0K | 2.95% | +20.4K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Keith A. Meisterincl. Eli Casdin, Casdin Partners GP, LLC +6 more | 17.90% | 5.36M | 13D | May 22, 2026 |
| Meister, Keith A.incl. Casdin Partners Master Fund, L.P., CMLS Holdings LLC +6 more | 17.90% | 5.36M | 13D | May 15, 2026 |
| Casdin Eliincl. Casdin Partners GP, LLC, Keith A. Meister +7 more | 14.20% | 4.10M | 13D | May 7, 2025 |
| The Goldman Sachs Group, Inc. | 5.80% | 1.73M | 13G | Aug 11, 2026 |
| BlackRock, Inc. | 5.50% | 1.62M | 13G | Jul 28, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 16, 2026 | Katherine Stuelanddirector, officer: CHIEF EXECUTIVE OFFICER | Sale · 5 lots | 10,501 | $97.61 | 115,476 |
| Sep 16, 2026 | Kevin Feeleyofficer: CHIEF FINANCIAL OFFICER | Sale · 5 lots | 3,728 | $97.61 | 44,945 |
| Sep 9, 2026 | Kevin Feeleyofficer: CHIEF FINANCIAL OFFICER | Sale | 1,285 | $84.22 | 41,476 |
| Sep 9, 2026 | Katherine Stuelanddirector, officer: CHIEF EXECUTIVE OFFICER | Sale | 3,692 | $84.22 | 107,227 |
| Sep 1, 2026 | Kevin Feeleyofficer: CHIEF FINANCIAL OFFICER | Sale | 372 | $83.84 | 40,299 |
| Jun 16, 2026 | Katherine Stuelanddirector, officer: CHIEF EXECUTIVE OFFICER | Sale · 3 lots | 10,501 | $60.77 | 104,372 |
| Jun 16, 2026 | Kevin Feeleyofficer: CHIEF FINANCIAL OFFICER | Sale · 3 lots | 3,729 | $60.77 | 39,954 |
| Jun 9, 2026 | Katherine Stuelanddirector, officer: CHIEF EXECUTIVE OFFICER | Sale | 3,639 | $53.77 | 96,123 |
| Jun 9, 2026 | Kevin Feeleyofficer: CHIEF FINANCIAL OFFICER | Sale | 1,266 | $53.77 | 36,486 |
| Jun 4, 2026 | Casdin Capital, LLCdirector, 10 percent owner: | Purchase | 150,000 | $56.44 | 3,657,164 |
House and Senate disclosures
Not reported.